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ABSTRACT
Objective: Right ventricular dysfunction (RVD) with myocardial damage may lead to fatal complications in patients with acute pulmonary embo-
lism (PE). Cytoplasmic heart-type fatty acid-binding protein (HFABP) and the N-terminal fragment of its prohormone (NT-proBNP) are sensitive 
and specific biomarkers of myocardial damage. We evaluated RVD and cardiac biomarkers for myocardial damage and short-term mortality in 
patients with acute PE.
Methods: We analyzed 41 patients (24 females, 17 males) with confirmed acute PE prospective. Three groups (massive, submassive, and non-
massive) of patients were defined, based on systemic systolic blood pressure measured on admission and RVD by transthoracic echocardiog-
raphy (TTE). Also, systolic (s) and mean (m) pulmonary artery pressures (PAPs) were recorded by TTE, and plasma concentrations of cardiac 
troponin T (cTn-T), NT-proBNP, and HFABP were evaluated 6 month follow-up.
Results: Seventeen (41.5%) patients experienced a complicated clinical course in the 6-month follow-up for the combined end-point, including 
at least one of the following: death (n=12, 29.3%; 3 PE-related), chronic PE (n=4, 9.8%), pulmonary hypertension (n=2, 4.9%), and recurrent PE 
(n=1, 2.4%). Multivariate hazard ratio analysis revealed HFABP, NT-proBNP, and PAPs as the 6-month mortality predictors (HR 1.02, 95% CI 1.01-
1.05; HR 1.01, 95% CI 1.01-1.04; and HR 1.02, 95% CI 1.02-1.05, respectively).
Conclusion: HFABP, NT-proBNP, and PAPs measured on admission may be useful for short-term risk stratification and in the prediction of 
6-month PE-related mortality in patients with acute PE. (Anatol J Cardiol 2016; 16: 276-82)
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Introduction
Cardiac biomarkers, such as cardiac troponin T (cTn-T), myo-
globin (Mb), brain natriuretic peptide (BNP), and the N-terminal 
fragment of its prohormone (NT-proBNP), as well as heart-type 
fatty acid-binding protein (HFABP), have been successfully used 
in the diagnosis of acute coronary syndromes (1) and congestive 
heart failure (2) for several years. It was recently shown that they 
are also potential useful prognostic biomarkers in patients with 
pulmonary embolism (PE) (3-5). It was demonstrated that the 
absence of cardiac troponin elevation can exclude an adverse 
in-hospital outcome with a high negative predictive value in 
patients with acute PE (3). Brain natriuretic peptides are highly 
sensitive indicators of neurohormonal activation resulting from 
ventricular dysfunction, and they can also be used to exclude a 
high mortality and complication risk in the acute phase of PE (6). 
Heart-type fatty acid-binding protein consists of small cytosolic 
molecules involved in intracellular transport of insoluble fatty 
acids and plays a major role in myocardial homeostasis, as 50% 
to 80% of cardiomyocyte energy is provided by lipid oxidation (7). 
It was shown that HFABP, as a biomarker, provides earlier and 
superior prognostic information than troponin in the first hours of 
acute coronary syndromes (8, 9). Recently, circulating HFABP 
levels have also been shown to be relevant for risk stratification in 
PE (5). Small cytoplasmic molecules, like myoglobin and HFABP, 
rise earlier (2-4 h) than bigger ones that are mainly associated 
with myofibrils, such as cardiac troponins (6-12 h) (5, 10). Because 
natriuretic prohormones are not stored in significant amounts in 
cardiomyocytes, it takes several hours for brain natriuretic-relat-
ed peptides to be released into circulation (11).
It was previously shown that right ventricular dysfunction 
(RVD) is an important determinant of outcome in patients with 
acute PE (12). Right ventricular dysfunction is an independent 
predictor of early mortality in PE not only for patients presenting 
with arterial hypotension and cardiogenic shock but also for 
normotensive patients (13). Acute submassive or massive PE 
also results in early damage to the (right ventricular) myocardi-
um. Therefore, after having confirmed PE, echocardiography 
may play an important role for risk stratification of patients pre-
senting with PE (14).
In the present study, we evaluated RVD and cardiac bio-
markers (HFABP, NT-proBNP, and cTn-T) for myocardial damage 
and short-term mortality in patients with acute PE.
Methods
Study population and design
Between October 2010 and May 2012, a total of 41 consecu-
tive patients (24 women; age 60.5±13.8 years) with confirmed 
acute PE were prospectively included in this trial over a period 
of 6 months. Acute PE was confirmed by contrast-enhanced 
computed tomography (CT) pulmonary angiography in 40 patients, 
and in addition ventilation-perfusion lung scan in one patient, in 
patients presenting to the emergency department of Pamukkale 
University Hospital with a clinical probability of PE (15). Patients 
with PE also underwent sonographic or phlebographic examina-
tion of the leg veins. Following a diagnosis of PE, transthoracic 
echocardiography (TTE) was performed to detect (or exclude) a) 
right ventricular dysfunction (dilatation of the right ventricle (RV) 
(end-diastolic diameter >30 mm from the parasternal view, or 
the RV appearing larger than the left ventricle (LV) from the sub-
costal or apical view, -RV/LV ratio >1, right ventricular ejection 
fraction (RVEF) <45%); b) systolic flattering of the interventricu-
lar septum; and c) the presence of right-sided cardiac thrombus 
(6). After measuring all of these parameters, right ventricular 
systolic pressure, a visual estimate of RV function, and the 
modified Simpson’s method for the estimation of right and left 
ventricular ejection fraction (EF) were performed by at least 5 
years experienced two echocardiographers (16, 17). A moder-
ately or severely impaired RV was defined as a right ventricular 
EF <45% (16). Neither the treating clinician nor the echocardiog-
raphers were aware of the patients’ cardiac biomarkers levels 
on admission. Our study did not influence the diagnostic or 
therapeutic decisions. 
Three groups (massive, submassive, and non-massive) of 
patients were defined, based on systemic systolic blood pres-
sure measured on admission and the result of the TTE (15). 
Acute PE was diagnosed as massive when systolic blood pres-
sure (SBP) was ≤90 mm Hg and RV overload was present in the 
TTE and submassive when SBP was >90 mm Hg and RV overload 
was present in the TTE, while the nonmassive acute PE group 
comprised patients with SBP >90 mm Hg, without echocardio-
graphic signs of RV overload. Death due to irreversible RV failure 
or recurrence of PE was considered PE-related death.
Complete data on baseline parameters and the patients’ 
treatments and outcomes were obtained using a standardized 
questionnaire (15) by investigators blinded to the biomarker lev-
els. The study design was observational, and biomarker levels 
were not used to guide patient management or to monitor the 
effects of treatment. 
Biomarker testing
Venous plasma and serum samples were obtained on admis-
sion, as well as 4, 8, and 24 h later, and were immediately stored 
at -80°C. Samples were later analyzed in batches after a single 
thaw. Serum cTnT levels were determined with the use of a 
commercial kit (Roche-Hitachi Diagnostics, Japan). For cTnT, a 
reference value of 0.03 ng/mL was used to distinguish between 
normal and elevated levels, as proposed by the manufacturer. 
Plasma concentrations of H-FABP and NT-proBNP were mea-
sured qualitatively using a commercial enzyme-linked immuno-
sorbent assay (ELISA) kit (Cusabio-China).
Statistical analysis
Statistical analyses were performed with the SPSS package 
program (version 11.0 for Windows, USA), and the results were 
presented as mean±standard deviation. Kruskal-Wallis test was 
used in the comparison of PE patient groups (massive, submas-
sive, and non-massive).
Continuous variables were compared using student’s t-test, 
and categorical variables were compared with Fisher exact test. 
Correlations between the variables (H-FABP, NT-proBNP, cTnT, 
PaO2, and PAPs) were analyzed by Pearson correlation test. The 
prognostic relevance of the markers with respect to mortality was 
estimated using univariate and multivariate Cox’s proportional 
hazard regression analysis. The results are presented as exact 
odds ratios (ORs) with corresponding 95% confidence intervals 
(CIs). A value of p<0.05 was considered statistically significant.
The study protocol was approved by the local Ethics 
Committee, and written informed consent was obtained from all 
patients. There was no funding to support this work. The authors 
are solely responsible for the design and conduct of the study, 
all study analyses, the drafting and editing of the paper, and its 
final contents.
Results
The baseline characteristics of all patients are presented in 
Table 1. Clinically, 18 patients (43.9%) had massive PE; 4 patients 
(9.8%) had submassive PE, and 19 patients (46.3%) had nonmas-
sive PE. There were no significant differences between age; 
gender; BMI; number of patients with hypertension, diabetes 
mellitus, smoker, cancer, COPD, and CAD; and history of recent 
surgery, PE, and venous thrombosis.
Right ventricular EF, systolic and mean PAPs, PaO2, and 
serum levels of HFABP, NT-proBNP, and cTn-T between the 
groups of patients with PE were significantly different (Table 2). 
For systolic and mean PAPs, the highest levels were observed in 
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patients with massive PE (65.9±22.3 mm Hg and 44.3±13.8 mm Hg 
respectively) compared to submassive PE (47.0±13.6 mm Hg, 
p=0.02 and 34.5±30.1 mm Hg, p=0.01) and nonmassive PE 
(39.2±22.7 mm Hg, p=0.002 and 28.9±18.3 mm Hg, p=0.003). Higher 
concentrations of HFABP (1.9±0.7 ng/mL vs. 1.6±0.5 ng/mL, 
p=0.03) and NT-proBNP (183.3±56.4 pg/mL vs. 113.1±29.7 pg/mL, 
p=0.02) were observed in patients with massive PE than in 
patients with non-massive PE. Concentrations of H-FABP 
(1.8±0.6 ng/mL) and NT-proBNP (160.1±38.4 pg/mL) in patients 
with submassive PE were also significantly higher than in 
patients with non-massive PE (1.6±0.5 ng/mL, p=0.04 and 
113.1±29.7 pg/mL, p=0.03). Although concentrations of H-FABP 
and NT-proBNP in patients with massive PE were higher than in 
patients with submassive PE, the difference did not reach statis-
tical significance. The highest concentrations of HFABP and 
NT-proBNP were observed in patients with massive PE, com-
pared to submassive and nonmassive PE. Also, the concentra-
tion of cTn-T (0.10±0.8 ng/mL) in patients with massive PE was 
significantly higher than in patients with non-massive PE 
(0.03±0.02 ng/mL, p=0.03) and in patients with submassive PE 
(0.05±0.03 ng/mL, p=0.04). Serum cTn-T levels between non-
massive and submassive patients with PE were not significantly 
different.
Twenty six (63.4%) patients were anticoagulated using either 
intravenous unfractionated heparin or subcutaneous low-
molecular-weight heparin. Fifteen (36.6%) patients initially pre-
senting with clinically massive or deteriorating submassive PE 
received thrombolysis, followed by intravenous heparin. Despite 
the treatment, 17 (41.5%) patients experienced clinical compli-
cations in the 6-month follow-up, including at least one of the 
following: death (n=12, 29.3%; 5 males, 7 females; 3 (7.3%) 
PE-related deaths and 9 (22%) due to co-existing diseases), 
chronic PE (n=4, 9.8%), pulmonary hypertension (n=2, 4.9%), and 
recurrent PE (n=1, 2.4%). Two deaths due to PE occurred in 
patients with massive PE and in 1 patient with initially non-
massive PE. Half of those 12 deaths (n=6, 14.6%) were seen in 
the 30-day follow-up.
Multivariate Cox’s proportional hazard regression analysis 
revealed that HFABP and NT-proBNP concentrations were 
6-month all-cause mortality predictors (χ2=47.5, p=0.001, HR 
1.02, 95% CI 1.01-1.06 and χ2=46.8, p=0.02, HR 1.03, 95% CI 1.02-
1.05). When only PE-related deaths (n=3) were considered, 
HFABP, NT-proBNP, and PAPs indicated 6-month mortality by 
multivariate hazard ratio analysis (HR 1.02, 95% CI 1.01-1.05; HR 
1.01, 95% CI 1.01-1.04; and HR 1.02, 95% CI 1.02-1.05, respec-
tively). While serum HFABP concentration was shown to have a 
significantly negative correlation with PaO2 (r=-0.401, p=0.02), it 
had a significantly positive correlation with PAPs (r=0.354, 
p=0.003) (Fig. 1). Like HFABP, serum NT-proBNP level had a sig-
nificantly negative correlation with PaO2 (r=-0.448, p=0.009) and 
a significantly positive correlation with PAPs (r=0.390, p=0.02) 
(Fig. 2). On the other hand, serum cTn-T levels also had a sig-
nificantly negative correlation with PaO2 (r=-0.357, p=0.04) and a 
significantly positive correlation with PAPs (r=0.366, p=0.03) 
(Fig. 3). Also, there were significantly positive correlations 
between H-FABP and NT-proBNP (r=0.770, p=0.0001); H-FABP 
and cTn-T (r=0.398, p=0.02); H-FABP and PAPs (r=0.354, p=0.03); 
NT-proBNP and cTn-T (r=0.402, p=0.02); and NT-proBNP and 
 Patients with PE
 Non-massive Sub-massive Massive 
 n: 19 n: 4 n: 18 
 (46.3%) (9.8%)  (43.9%) P*
Age, year 60.8±15.2 62.3±9.9 59.7±13.7 NS
Female (n, %) 10 (52.6) 3 (75.0) 11 (61.1) NS
Male (n, %) 9 (47.4) 1 (25.0) 7 (38.9) NS
Hypertension (n, %) 10 (52.6) 1 (25.0) 6 (33.3) NS
Diabetes mellitus 3 (15.8) 0 (0) 1 (5.6) NS 
(n, %)
BMI ≥30 kg/m2 (n, %) 2 (10.5) 1 (25.0) 3 (16.7) NS
Smoker (n, %) 0 (0) 2 (50.0) 2 (11.1) NS
Cancer (n, %) 6 (31.6) 1 (25.0) 5 (27.8) NS
Recent surgery (n, %) 3 (15.8) 0 (0) 4 (22.2) NS
History of PE (n, %) 1 (5.3) 0 (0) 0 (0) NS
History of venous 11 (57.9) 2 (50.0) 8 (44.4) NS 
thrombosis (n, %)
COPD (n, %) 3 (15.8) 1 (25.0) 5 (27.8) NS
CAD (n, %) 2 (10.5) 0 (0) 3 (16.7) NS
BMI - body mass index; CAD - coronary artery disease; COPD - chronic obstructive pulmonary 
disease; NS - not significant; PE - pulmonary embolism *Kruskal-Wallis test used
Table 1. Baseline characteristics in subgroups of patients with pulmonary 
embolism
 Patients with PE
 Non-massive Sub-massive Massive 
 n: 19 n: 4 n: 18 
 (46.3%) (9.8%)  (43.9%) P*
RVEF, % 54.5±4.5 43.8±4.3 38.4±4.0 0.01
LVEF, % 60.4±5.1 58.3±5.0 56.7±4.9 NS
PAPsystolic, mm Hg 39.2±22.7 47.0±13.6 65.9±22.3 0,01
PAPmean, mm Hg 28.9±18.3 34.5±30.1 44.3±13.8 0.01
PaO2, mm Hg 64.0±11.0 54.7±10.2  48.3±13.2 0.03
HFABP, ng/mL 1.6±0.5  1.8±0.6 1.9±0.7 0.04
NT-proBNP, pg/mL 113.1±29.7 160.1±38.4 183.3±56.4 0.05
cTn-T, ng/mL 0.03±0.02 0.05±0.03 0.10±0.8 0.04
Myoglobin, ng/mL 66.8±52.2 72.9±88.3 69.6±87.9 NS
CK-MB, ng/mL 3.2±2.3 9.8±7.2  12.1±8.9 NS
CRP, mg/dL 4.7±3.5 6.6±4.9 6.1±5.3 NS
*Between the 3 groups. CK-MB - creatinine kinase myocardial band; CRP - C-reactive 
protein; cTn-T - cardiac troponin T; HFABP - heart-type fatty acid-binding, protein; LVEF - 
left ventricular ejection fraction; NS - not significant; NT-proBNP - N-terminal 
prohormone brain natriuretic peptide; PaO2 - pressure of arterial oxygen; PAP - pulmonary 
artery pressure; RVEF - right ventricular ejection fraction *Kruskal-Wallis test used
Table 2. Echocardiographic and laboratory findings on admission in 41 
patients with pulmonary embolism (PE)
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PAPs (r=0.390, p=0.02) (Table 3). However, there were significantly nega-
tive correlations between H-FABP and PaO2 (r=-0.401, p=0.02); NT-proBNP 
and PaO2 (r=-0.448, p=0.009); and cTn-T and PaO2 (r=-0.357, p=0.04).
Discussion
The present study showed that right ventricular EF, systolic 
and mean PAPs, PaO2, and serum levels of HFABP, NT-proBNP, 
and cTn-T between the groups of patients with PE were signifi-
cantly different. The highest levels of systolic and mean PAPs 
and concentrations of HFABP, NT-proBNP, and cTn-T were 
observed in patients with massive PE. Also, 17 patients (41.5%) 
experienced a complicated clinical course in the 6-month fol-
low-up for the combined end-point, including at least one of the 
following: death (n=12, 29.3%), chronic PE (n=4, 9.8%), pulmo-
nary hypertension (n=2, 4.9%), and recurrent PE (n=1, 2.4%). The 
multivariate hazard ratio analysis revealed HFABP, NT-proBNP, 
and PAPs as 6-month mortality predictors.
The size of the embolus and the underlying cardiopulmonary 
function are the most determinants of morbidity and mortality in 
Correlations* r P
H-FABP and NT-proBNP 0.770 0.0001
H-FABP and cTn-T 0.398 0.02
NT-proBNP and cTn-T 0.402 0.02
H-FABP and PaO2 -0.401 0.02
H-FABP and PAPs 0.354 0.03
NT-proBNP and PaO2 -0.448 0.009
NT-proBNP and PAPs 0.390 0.02
cTn-T and PaO2 -0.357 0.04
Pearson's correlation test. cTn-T - cardiac troponin, HFABP - heart-type fatty acid-
binding, NT-proBNP - N-terminal prohormone brain natriuretic peptide; PaO2 - 
pressure of arterial oxygen
Table 3. Correlations between H-FABP, NT-proBNP, cTn-T, and PaO2 in 
patients with pulmonary embolism
Figure 1. Correlations between HFBAP and PaO2 and PAPs in patients 
with pulmonary embolism 
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Figure 2. Correlations between NT-proBNP and PaO2 and PAPs in 
patients with pulmonary embolism 
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Figure 3. Correlations between cTn-T and PaO2 and PAPs in patients 
with pulmonary embolism
Pearson's correlation test
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patients with acute PE. A sudden increase in pressure load on 
the right ventricle and the increased pulmonary artery pressure 
may not be tolerated due to the inability of its thin wall to devel-
op and sustain high wall tension and stress. The increase in RV 
pressures may result in the shifting of the interventricular sep-
tum toward the left ventricle, reducing the LV volume. Right 
ventricular dysfunction due to PE results from a combination of 
increased myocardial wall stress and PAPs and cardiac isch-
emia (18). It is important to risk-stratify patients with PE at pre-
sentation for the management strategy. Although patients with 
hemodynamic instability at presentation have high mortality, 
hemodynamically stable patients with RVD have also high mor-
tality; however, these patients are more difficult to recognize 
(12). Echocardiography has traditionally been used to identify 
these high-risk normotensive patients. In the present study, right 
ventricular EF was significantly at the lowest level (38.4±4.0%) in 
patients with massive PE, compared to submassive and non-
massive PE patients (Table 2). For systolic and mean PAPs, the 
highest levels were observed in patients with massive PE 
(65.9±22.3 mm Hg and 44.3±13.8 mm Hg) compared to submas-
sive PE (47.0±13.6 mm Hg, p=0.02 and 34.5±30.1 mm Hg, p=0.01) 
and nonmassive PE (39.2±22.7 mm Hg, p=0.002 and 28.9±18.3 mm 
Hg, p=0.003). In addition, patients with massive PE had the low-
est level of PaO2 (48.3±13.2 mm Hg) significantly. The importance 
of identifying RVD in acute PE has been demonstrated by pro-
spective cohort studies. In a registry of 1035 normotensive 
patients with acute PE, RVD was detected by echocardiography 
in 39% of patients, with RVD being an independent predictor of 
30-day mortality (13). However, in a study involving patients with 
massive PE, metabolic acidosis, but not echocardiography mea-
surements, was an independent predictor of mortality in the 
multivariate analysis (19). On the other hand, it was shown that 
of the 529 study patients with normotensive PE, 25 (4.7%) had at 
least one outcome event, defined as death, recurrent PE, or 
shock, within the 30-day follow-up (20).
Echocardiography may not always be available, and there is 
the potential for biomarkers to provide additive prognostic infor-
mation. The relation between natriuretic peptide levels and the 
prognosis in acute PE has recently been explored in several 
systematic reviews (11, 14, 21-23). Myocardial wall stress is a 
potent stimulus for the increased synthesis and secretion of 
BNP and NT-proBNP (24). Tulevski et al. (25) showed that 29% of 
normotensive patients had increased BNP and normal troponin 
T at presentation; in half of them, BNP remained increased after 
treatment, and they were diagnosed with chronic PE and RV 
pressure overload during the follow-up. The results of a meta-
analysis indicate that both BNP and NT-proBNP are associated 
with the diagnosis of RVD and are also significant predictors of 
all-cause in-hospital or short-term mortality in patients with 
acute PE (11). In the present study, serum levels of NT-proBNP, 
HFABP, and cTn-T were significantly different between the 
groups of patients with PE. The highest concentrations of 
NT-proBNP, HFABP, and cTn-T were observed in patients with 
massive PE, compared to the submassive and nonmassive 
groups (Table 2). In comparing serum cardiac biomarkers 
between nonmassive and submassive patients with PE, only 
serum cTn-T levels were not significantly different. In our study, 
17 (41.5%) patients experienced complicated a clinical course in 
the 6-month follow-up for the combined end-point, including at 
least one of the following: 12 deaths, 2 pulmonary hypertension 
(4.9%), and 1 recurrent PE (2.4%). However, half of those 12 
deaths (14.6%) were seen in the 30-day follow-up. In the present 
study, the multivariate hazard ratio analysis revealed HFABP, 
NT-proBNP, and PAPs as the 6-month mortality predictors (HR 
1.02, 95% CI 1.01-1.05; HR 1.01, 95% CI 1.01-1.04; and HR 1.02, 95% 
CI 1.02-1.05, respectively). In a study including 234 consecutive 
patients with acute PE, 52 (22%) patients had died, and age (OR 
4.37, 95% CI 1.04-1.16) and NT-ProBNP (OR 1.49, 95% CI 1-1.002) 
were independent factors of mortality at a median time of 9.5 
months (26). Also, a prospective cohort study included a total of 
1078 patients from a multi-center registry with objectively con-
firmed acute symptomatic PE; the all-cause mortality rate was 
8.8% within 30 days of diagnosis (27). In a recent prospective 
cohort study, a complicated course occurred in 63 (7.4%) of the 
848 normotensive patients with acute symptomatic PE (28). Also, 
in a study including 61 patients with PE at intermediate risk, it 
was reported that 11 patients died due to PE (18% mortality rate) 
during the 30-day follow-up period (29).
A recent meta-analysis demonstrated that elevated levels of 
troponins were predictive of short-term death in normotensive 
patients with acute PE (30). Microinfarction in the right ventricle 
can be potentially detected by even small increases in troponin 
levels (31). Cardiac troponins are highly sensitive and specific 
indicators of myocardial cell damage, and elevated troponin 
levels were correlated with in-hospital mortality or complica-
tions in unselected patients with acute PE (32). However, intra-
cellular HFABP tends to appear early in the circulation after 
myocardial injury. Puls et al. (33) showed that HABP is superior 
to NT-proBNP and cTn-T for predicting 30-day mortality or a 
complicated outcome in 107 consecutive patients with acute PE. 
In a study, during the first 30 days, 7% of patients with acute PE 
who had higher baseline H-FABP values suffered complications 
(34). It was shown that of the 101 consecutive patients with 
confirmed PE at intermediate risk, 14 had positive H-FABP tests, 
10 (71%) had clinical deterioration during the hospital course 
and required inotropic support, and 8 (57%) died (35). In that 
study, H-FABP significantly predicted mortality in patients with 
PE at intermediate risk, and it was also significantly associated 
with impaired RV function and showed better correlation with 
mortality than troponin I. In a cross-sectional observational 
study including 30 hemodynamically stable patients with acute 
PE, systolic and diastolic eccentricity indexes were found to 
have a significant correlation with serum troponin I (respec-
tively, r=0.470, p=0.009; r=0.310, p=0.095) and BNP (respectively, 
r=0.402, p=0.028; r=0.384, p=0.036) values (36). It was shown that 
pulmonary hypertension (~74%) was the most common echocar-
diographic finding in patients with PE and elevated cTnI levels 
(37). Hereby, we also showed significantly positive correlations 
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between H-FABP, NT-proBNP, and cTn-T (Table 3). While serum 
HFABP concentration had a significantly negative correlation 
with PaO2 (r=-0.401, p=0.02), it had a significantly positive cor-
relation with PAPs (r=0.354, p=0.003) (Fig. 1). Like HFABP, serum 
NT-proBNP level had a significantly negative correlation with 
PaO2 (r=-0.448, p=0.009) and a significantly positive correlation 
with PAPs (r=0.390, p=0.02) (Fig. 2). On the other hand, serum 
cTn-T levels also had a significantly negative correlation with 
PaO2 (r=-0.357, p=0.04) and a significantly positive correlation 
with PAPs (r=0.366, p=0.03) (Fig. 3). Our study results confirm that 
there may be a relationship between cardiac biomarkers, arte-
rial hypoxemia, pulmonary hypertension, and RV dysfunction in 
patients with PE.
Study limitations
The main limitation of this study is related to the small num-
ber of patients (especially in the massive PE group) included. 
Additionally, NT-proBNP for the diagnosis of RVD in acute PE 
has low specificity. It is elevated in a range of conditions that 
lead to ventricular dilatation and pressure overload, and there is 
experimental evidence that mechanisms other than myocardial 
stretch may also elevate their levels (38).
Conclusion
Right ventricular EF, systolic and mean PAPs, PaO2, and serum 
levels of HFABP, NT-proBNP, and cTn-T were significantly different 
between the three groups of patients with PE. The highest con-
centrations of HFABP, NT-proBNP, and cTn-T were observed in 
patients with massive PE, compared to the submassive and non-
massive groups. Therefore, a multi-cardiac biomarker approach in 
association with echocardiographic evaluation may provide more 
meaningful short-term risk stratification and in the prediction of 
6-month PE-related mortality of patients with acute PE.
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